These data, collectively, suggest that midostaurin and the other investigated FLT3 inhibitors are effective against wt FLT3‐expressing AML cells with concentration‐dependent killing at concentrations of 1 μmol/L or less. The gene discussed is FLT3; the disease is acute myeloid leukemia.